PT1768966E - Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação - Google Patents
Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação Download PDFInfo
- Publication number
- PT1768966E PT1768966E PT05762701T PT05762701T PT1768966E PT 1768966 E PT1768966 E PT 1768966E PT 05762701 T PT05762701 T PT 05762701T PT 05762701 T PT05762701 T PT 05762701T PT 1768966 E PT1768966 E PT 1768966E
- Authority
- PT
- Portugal
- Prior art keywords
- coumpounds
- inhibiting
- interaction
- methods
- binding partners
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58061604P | 2004-06-17 | 2004-06-17 | |
| US65930105P | 2005-03-07 | 2005-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1768966E true PT1768966E (pt) | 2012-05-23 |
Family
ID=35335774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05762701T PT1768966E (pt) | 2004-06-17 | 2005-06-17 | Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7851637B2 (OSRAM) |
| EP (1) | EP1768966B1 (OSRAM) |
| JP (1) | JP5064213B2 (OSRAM) |
| KR (1) | KR101195351B1 (OSRAM) |
| CN (1) | CN101006065B (OSRAM) |
| AT (1) | ATE548359T1 (OSRAM) |
| AU (1) | AU2005265131B2 (OSRAM) |
| BR (1) | BRPI0511070A (OSRAM) |
| CA (1) | CA2570780C (OSRAM) |
| EC (1) | ECSP067099A (OSRAM) |
| ES (1) | ES2382383T3 (OSRAM) |
| IL (1) | IL179904A (OSRAM) |
| MA (1) | MA28702B1 (OSRAM) |
| MX (1) | MXPA06014754A (OSRAM) |
| NO (1) | NO20070324L (OSRAM) |
| NZ (1) | NZ552183A (OSRAM) |
| PL (1) | PL1768966T3 (OSRAM) |
| PT (1) | PT1768966E (OSRAM) |
| RU (1) | RU2416606C2 (OSRAM) |
| WO (1) | WO2006009869A1 (OSRAM) |
| ZA (1) | ZA200610405B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842815B2 (en) * | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| CA2570780C (en) | 2004-06-17 | 2013-12-03 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 |
| TWI389895B (zh) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| EP1897956A1 (en) | 2006-09-06 | 2008-03-12 | Lonza AG | Process for preparation of optically active amines by optical resolution of racemic amines employing a bacterial omega-transaminase |
| JP2011511076A (ja) * | 2008-02-08 | 2011-04-07 | エイルロン セラピューティクス，インコーポレイテッド | 治療用ペプチド模倣大環状分子 |
| US20110086834A1 (en) * | 2008-06-26 | 2011-04-14 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| DK2321640T3 (en) | 2008-08-21 | 2017-02-27 | Immunogenics Llc | FORMULATION FOR ORAL ADMINISTRATION OF PROTEINS |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| UA108193C2 (uk) * | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| CA2744711C (en) * | 2008-12-05 | 2017-06-27 | Abbott Laboratories | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8546399B2 (en) * | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PE20120345A1 (es) * | 2009-05-26 | 2012-05-17 | Abbvie Bahamas Ltd | Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas |
| US8314250B2 (en) | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| EP3099380B1 (en) | 2014-01-28 | 2021-08-11 | Buck Institute for Research on Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US10709692B2 (en) * | 2015-12-04 | 2020-07-14 | Denali Therapeutics Inc. | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) |
| NZ757763A (en) | 2016-03-28 | 2025-07-25 | Presage Biosciences Inc | Pharmaceutical combinations for the treatment of cancer |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS55133364A (en) * | 1979-04-03 | 1980-10-17 | Mitsubishi Petrochem Co Ltd | Preparation of isoxazolidine derivative |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| DE3643012A1 (de) * | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| DE3829594A1 (de) * | 1988-09-01 | 1990-03-15 | Bayer Ag | Neue renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln |
| DE3926822A1 (de) * | 1989-08-14 | 1991-02-21 | Hoechst Ag | Peptide mit bradykinin-antagonistischer wirkung |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| RU2142937C1 (ru) | 1990-05-18 | 1999-12-20 | Хехст АГ | Амиды органических кислот, способ их получения и фармацевтическая композиция |
| US5294617A (en) | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| BR9408137A (pt) | 1993-11-24 | 1997-08-12 | Du Pont Merck Pharma | Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição |
| DE69422061T2 (de) * | 1993-11-26 | 2000-03-30 | Pfizer, Inc. | 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel |
| KR100200449B1 (ko) | 1994-03-09 | 1999-06-15 | 디. 제이. 우드, 스피겔 알렌 제이 | Tnf 방출 억제제로서의 이소옥사졸린 화합물 |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| US5514505A (en) | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| DE19539638A1 (de) | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
| US6221865B1 (en) * | 1995-11-06 | 2001-04-24 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| IT1283836B1 (it) | 1996-08-28 | 1998-04-30 | Viv Int Spa | Procedimento per decorare profilati metallici,in materiale plastico e simili e relativa apparecchiatura |
| AU5239198A (en) | 1996-10-16 | 1998-05-11 | President And Fellows Of Harvard College, The | Droplet assay system |
| AR015649A1 (es) * | 1997-05-07 | 2001-05-16 | Univ Pittsburgh | Inhibidores de isoprenil-transferasas proteicas, composiciones que los comprenden y el uso de los mismos para la fabricacion de un medicamento |
| AU7105800A (en) | 1999-09-01 | 2001-03-26 | Chemrx Advanced Technologies, Inc. | Process for synthesizing isoxazolidines |
| KR100399361B1 (ko) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| ES2349349T3 (es) | 2001-05-30 | 2010-12-30 | The Regents Of The University Of Michigan | Asociacion sinergica de (-)-gosipol con docetaxel o paclitaxel para el tratamiento de cancer. |
| US20030119894A1 (en) | 2001-07-20 | 2003-06-26 | Gemin X Biotechnologies Inc. | Methods for treatment of cancer or neoplastic disease and for inhibiting growth of cancer cells and neoplastic cells |
| FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
| CA2570780C (en) | 2004-06-17 | 2013-12-03 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
-
2005
- 2005-06-17 CA CA2570780A patent/CA2570780C/en not_active Expired - Fee Related
- 2005-06-17 AU AU2005265131A patent/AU2005265131B2/en not_active Ceased
- 2005-06-17 JP JP2007516793A patent/JP5064213B2/ja not_active Expired - Fee Related
- 2005-06-17 US US11/156,364 patent/US7851637B2/en not_active Expired - Fee Related
- 2005-06-17 RU RU2007101276/04A patent/RU2416606C2/ru not_active IP Right Cessation
- 2005-06-17 KR KR1020077001087A patent/KR101195351B1/ko not_active Expired - Fee Related
- 2005-06-17 PL PL05762701T patent/PL1768966T3/pl unknown
- 2005-06-17 ES ES05762701T patent/ES2382383T3/es not_active Expired - Lifetime
- 2005-06-17 AT AT05762701T patent/ATE548359T1/de active
- 2005-06-17 BR BRPI0511070-0A patent/BRPI0511070A/pt active Search and Examination
- 2005-06-17 MX MXPA06014754A patent/MXPA06014754A/es active IP Right Grant
- 2005-06-17 CN CN2005800281288A patent/CN101006065B/zh not_active Expired - Fee Related
- 2005-06-17 WO PCT/US2005/021524 patent/WO2006009869A1/en not_active Ceased
- 2005-06-17 NZ NZ552183A patent/NZ552183A/en not_active IP Right Cessation
- 2005-06-17 PT PT05762701T patent/PT1768966E/pt unknown
- 2005-06-17 EP EP05762701A patent/EP1768966B1/en not_active Expired - Lifetime
-
2006
- 2006-12-07 IL IL179904A patent/IL179904A/en not_active IP Right Cessation
- 2006-12-12 ZA ZA200610405A patent/ZA200610405B/en unknown
- 2006-12-20 EC EC2006007099A patent/ECSP067099A/es unknown
- 2006-12-29 MA MA29588A patent/MA28702B1/fr unknown
-
2007
- 2007-01-17 NO NO20070324A patent/NO20070324L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2570780C (en) | 2013-12-03 |
| NO20070324L (no) | 2007-03-19 |
| MXPA06014754A (es) | 2007-06-22 |
| RU2416606C2 (ru) | 2011-04-20 |
| ES2382383T3 (es) | 2012-06-07 |
| IL179904A0 (en) | 2007-05-15 |
| CN101006065A (zh) | 2007-07-25 |
| US7851637B2 (en) | 2010-12-14 |
| IL179904A (en) | 2011-11-30 |
| JP2008503489A (ja) | 2008-02-07 |
| ECSP067099A (es) | 2007-04-26 |
| JP5064213B2 (ja) | 2012-10-31 |
| KR20070046068A (ko) | 2007-05-02 |
| HK1105963A1 (en) | 2008-02-29 |
| MA28702B1 (fr) | 2007-06-01 |
| RU2007101276A (ru) | 2008-08-10 |
| KR101195351B1 (ko) | 2012-10-29 |
| CA2570780A1 (en) | 2006-01-26 |
| BRPI0511070A (pt) | 2007-11-27 |
| CN101006065B (zh) | 2012-07-11 |
| AU2005265131A1 (en) | 2006-01-26 |
| EP1768966A1 (en) | 2007-04-04 |
| EP1768966B1 (en) | 2012-03-07 |
| WO2006009869A1 (en) | 2006-01-26 |
| AU2005265131B2 (en) | 2012-02-23 |
| PL1768966T3 (pl) | 2012-08-31 |
| NZ552183A (en) | 2009-10-30 |
| ZA200610405B (en) | 2008-03-26 |
| US20060025460A1 (en) | 2006-02-02 |
| ATE548359T1 (de) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009005184A (es) | Compuestos y metodos para inhibir la interaccion de las proteinas bcl con agentes aglutinantes. | |
| PL1768966T3 (pl) | Związki i sposoby hamowania oddziaływania białek BCL z partnerami wiążącymi | |
| JO2917B1 (en) | Compounds and methods to inhibit the interaction between BCL and binding partners | |
| TNSN08258A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| TW200738234A (en) | Triazole compounds that modulate HSP90 activity | |
| TW200637831A (en) | Triazole compounds that modulate Hsp90 activity | |
| WO2007139960A3 (en) | Compounds that modulate hsp90 activity and methods for identifying same | |
| MX2010001565A (es) | Compuestos triazolicos que modulan la actividad de proteina de choque termico (hsp) 90. | |
| MX2009008547A (es) | Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer. | |
| WO2006122156A3 (en) | Compounds for modulating trpv3 function | |
| WO2007056124A3 (en) | Compounds for modulating trpv3 function | |
| WO2007139967A3 (en) | Triazole compounds that modulate hsp90 activity | |
| WO2007139955A8 (en) | Triazole compounds that modulate hsp90 activity | |
| WO2007139968A3 (en) | Triazole compounds that modulate hsp90 activity | |
| TW200738683A (en) | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation | |
| WO2009056631A3 (en) | Molecules and methods for modulating complement component | |
| WO2003084475A3 (en) | INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME | |
| WO2007022947A3 (de) | 5-ring-heteroaromaten-verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren | |
| WO2004060878A3 (en) | Inhibitors of phosphatases | |
| TNSN06418A1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| MY155908A (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| TW200621265A (en) | Composition for treating tumor and/or preventing tumor transfer and recurrence | |
| TW200800952A (en) | Biaryl compositions and methods for modulating a kinase cascade | |
| HK1136570A1 (zh) | 用於调节激酶级联反应的组合物与方法 |